JP2013519699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519699A5 JP2013519699A5 JP2012553267A JP2012553267A JP2013519699A5 JP 2013519699 A5 JP2013519699 A5 JP 2013519699A5 JP 2012553267 A JP2012553267 A JP 2012553267A JP 2012553267 A JP2012553267 A JP 2012553267A JP 2013519699 A5 JP2013519699 A5 JP 2013519699A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- domain
- fviii
- another embodiment
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 38
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 38
- 108010054218 Factor VIII Proteins 0.000 claims description 18
- 102000001690 Factor VIII Human genes 0.000 claims description 18
- 229960000301 factor viii Drugs 0.000 claims description 18
- 230000004927 fusion Effects 0.000 claims description 17
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 108010087819 Fc receptors Proteins 0.000 claims description 11
- 102000009109 Fc receptors Human genes 0.000 claims description 11
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 10
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 5
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 102000002110 C2 domains Human genes 0.000 claims description 3
- 108050009459 C2 domains Proteins 0.000 claims description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 31
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 230000004989 O-glycosylation Effects 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 108010068617 neonatal Fc receptor Proteins 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 108090001126 Furin Proteins 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- -1 for example Chemical class 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10153715 | 2010-02-16 | ||
| EP10153715.7 | 2010-02-16 | ||
| US30617710P | 2010-02-19 | 2010-02-19 | |
| US61/306,177 | 2010-02-19 | ||
| PCT/EP2011/051959 WO2011101284A1 (en) | 2010-02-16 | 2011-02-10 | Factor viii fusion protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016021624A Division JP6185097B2 (ja) | 2010-02-16 | 2016-02-08 | 因子viii融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013519699A JP2013519699A (ja) | 2013-05-30 |
| JP2013519699A5 true JP2013519699A5 (enExample) | 2015-07-02 |
Family
ID=42244627
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012553267A Withdrawn JP2013519699A (ja) | 2010-02-16 | 2011-02-10 | 因子viii融合タンパク質 |
| JP2016021624A Expired - Fee Related JP6185097B2 (ja) | 2010-02-16 | 2016-02-08 | 因子viii融合タンパク質 |
| JP2017144266A Withdrawn JP2017190342A (ja) | 2010-02-16 | 2017-07-26 | 因子viii融合タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016021624A Expired - Fee Related JP6185097B2 (ja) | 2010-02-16 | 2016-02-08 | 因子viii融合タンパク質 |
| JP2017144266A Withdrawn JP2017190342A (ja) | 2010-02-16 | 2017-07-26 | 因子viii融合タンパク質 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9493543B2 (enExample) |
| EP (2) | EP2977055A1 (enExample) |
| JP (3) | JP2013519699A (enExample) |
| CN (2) | CN105153313A (enExample) |
| WO (1) | WO2011101284A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011028228A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
| CN102770449B (zh) * | 2010-02-16 | 2016-02-24 | 诺沃—诺迪斯克有限公司 | 具有降低的vwf结合的因子viii分子 |
| CN104271150A (zh) * | 2012-01-12 | 2015-01-07 | 比奥根艾迪克Ma公司 | 嵌合因子viii多肽及其用途 |
| CA2864126A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| ES2935489T3 (es) | 2012-02-15 | 2023-03-07 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
| WO2013083858A1 (en) | 2012-04-24 | 2013-06-13 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| JP2015519313A (ja) | 2012-04-24 | 2015-07-09 | ノヴォ ノルディスク アー/エス | 血友病の治療に適する医薬組成物 |
| NZ703366A (en) | 2012-07-11 | 2018-03-23 | Amunix Operating Inc | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
| US9815871B2 (en) | 2013-04-23 | 2017-11-14 | President And Fellows Of Harvard College | Genetic reprogramming of bacterial biofilms |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| JP6463361B2 (ja) | 2013-09-08 | 2019-01-30 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | 第viii因子両性イオンポリマーコンジュゲート |
| PL3091997T3 (pl) | 2014-01-10 | 2023-01-02 | Bioverativ Therapeutics Inc. | Białka chimeryczne czynnika viii i ich zastosowania |
| EP3114138B1 (en) * | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3177317B1 (en) | 2014-08-04 | 2020-03-18 | CSL Limited | Factor viii formulation |
| KR20210013299A (ko) | 2014-10-17 | 2021-02-03 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
| SG11201706659WA (en) | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| EP3280397A4 (en) | 2015-04-06 | 2018-08-22 | President and Fellows of Harvard College | Biosynthetic amyloid-based materials displaying functional protein sequences |
| WO2016198521A1 (en) * | 2015-06-10 | 2016-12-15 | Novo Nordisk A/S | Fviii fusion proteins |
| CN104926946B (zh) * | 2015-07-13 | 2021-09-17 | 中国科学院广州生物医药与健康研究院 | 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用 |
| MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
| CN107921103A (zh) | 2015-08-12 | 2018-04-17 | 细胞机械股份有限公司 | 涉及长半衰期凝血复合物的方法和组合物 |
| GB201520021D0 (en) * | 2015-11-13 | 2015-12-30 | Asterion Ltd | Fusion polypeptide |
| NZ744185A (en) | 2015-12-30 | 2025-09-26 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| US11098133B2 (en) | 2016-05-19 | 2021-08-24 | President And Fellows Of Harvard College | Methods of making gels and films using curli nanofibers |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| WO2018032638A1 (zh) | 2016-08-19 | 2018-02-22 | 安源医药科技(上海)有限公司 | 用于构建融合蛋白的连接肽 |
| CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技(上海)有限公司 | 双特异性抗体及其制备方法与用途 |
| IL319473A (en) | 2016-12-02 | 2025-05-01 | Bioverativ Therapeutics Inc | Methods for treating hemophilic arthritis using chimeric blood clotting factors |
| CN108623695B (zh) * | 2017-03-24 | 2022-03-15 | 中国科学院过程工程研究所 | 一种白蛋白结合肽-人睫状神经营养因子融合蛋白及其制备方法和应用 |
| CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
| GB201706781D0 (en) | 2017-04-28 | 2017-06-14 | Univ Sheffield | Parathyroid hormone fusion polypeptide |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| US12440572B2 (en) * | 2018-05-18 | 2025-10-14 | Zhengzhou Gensciences Inc. | FVIII fusion protein and use thereof |
| WO2019219048A1 (zh) * | 2018-05-18 | 2019-11-21 | 北京辅仁瑞辉生物医药研究院有限公司 | 具有延长半衰期的融合多肽缀合物 |
| DK3793588T3 (da) | 2018-05-18 | 2025-06-16 | Bioverativ Therapeutics Inc | Fremgangsmåder til behandling af hæmofili a |
| CN110950964B (zh) * | 2018-09-26 | 2021-06-18 | 安源医药科技(上海)有限公司 | 突变型单链人凝血因子viii融合蛋白及其制备方法与用途 |
| CN114072420B (zh) | 2019-07-04 | 2024-06-11 | 康诺贝林伦瑙有限公司 | 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf) |
| EP3785726A1 (en) | 2019-09-02 | 2021-03-03 | Biotest AG | Factor viii protein with increased half-life |
| AU2020342349A1 (en) * | 2019-09-02 | 2022-03-03 | Biotest Ag | Factor VIII protein with increased half-life |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| EP4058049A1 (en) | 2019-11-11 | 2022-09-21 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
| KR20220130692A (ko) * | 2020-01-20 | 2022-09-27 | 우시 바이올로직스 아일랜드 리미티드 | 친화성 크로마토그래피를 위한 신규한 세척 완충제 용액 |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| JP2023542389A (ja) * | 2020-09-23 | 2023-10-06 | アブレヴィア バイオテック ゲーエムベーハー | 自己抗体で媒介される状態の予防又は治療のための化合物 |
| TWI878902B (zh) * | 2022-05-25 | 2025-04-01 | 大陸商江蘇晟斯生物製藥有限公司 | 具有延長的半衰期的fviii融合蛋白綴合物及其應用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988009343A1 (fr) | 1987-05-29 | 1988-12-01 | Sagami Chemical Research Center | Proteine fusionnee contenant une lymphotoxine |
| AU2645588A (en) | 1987-12-04 | 1989-06-15 | Scripps Clinic And Research Foundation | The von willebrand factor binding domain of factor viii |
| US5843440A (en) | 1990-10-03 | 1998-12-01 | Redcell Canada, Inc. | Cellular and serum protein anchors for modulating pharmacokinetics |
| US6939677B1 (en) | 1990-11-01 | 2005-09-06 | Cancer Research Fund Of Contra Costa | Antibody with 46 kdalton HMFG antigen binding specificity, immunoassay kit and diagnostic method |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6524572B1 (en) | 2000-06-26 | 2003-02-25 | Rainbow Therapeutic Company | Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy |
| EP2305311A3 (en) | 2001-10-10 | 2011-07-20 | BioGeneriX AG | Glycoconjugation of peptides |
| EP2272533A1 (en) | 2003-01-13 | 2011-01-12 | MacroGenics, Inc. | Soluble FcyR fusion proteins and methods of use thereof |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| WO2005040382A2 (de) | 2003-10-28 | 2005-05-06 | Alexander Cherkasky | Cherkasky - fusionsproteine enthaltend antikorperbinde-, antigenbinde - mikrotubulibinde und immunantwortauslosende |
| WO2005113584A1 (en) | 2004-04-29 | 2005-12-01 | Board Of Regents, University Of Texas System | Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting |
| ATE527371T1 (de) | 2005-03-24 | 2011-10-15 | Biogenerix Ag | Expression löslicher, aktiver, eukaryotischer glucosyltransferasen in prokaryotischen organismen |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| WO2007065691A2 (en) | 2005-12-07 | 2007-06-14 | Technische Universität München | Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins |
| EP1980615A4 (en) | 2006-01-31 | 2010-04-21 | Ishihara Sangyo Kaisha | POLYPEPTIDE WITH AFFINITY FOR A CURVED VIRUS COMPONENT AND USE THEREOF IN THE TRANSFER OF A SUBSTANCE INTO A CELL |
| ES2531934T3 (es) * | 2006-09-01 | 2015-03-20 | Novo Nordisk Health Care Ag | Glicoproteínas modificadas |
| US20080267949A1 (en) | 2006-12-05 | 2008-10-30 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| AU2007338298B2 (en) * | 2006-12-22 | 2013-02-07 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| AU2008209436A1 (en) * | 2007-01-23 | 2008-07-31 | Zymogenetics, Inc. | Soluble Fc gamma R1a for reducing inflammation |
| US8043621B2 (en) | 2007-05-10 | 2011-10-25 | Ramot At Tel Aviv University Ltd. | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
| JP5314033B2 (ja) * | 2007-10-22 | 2013-10-16 | メルク セローノ ソシエテ アノニム | 突然変異IgGFcフラグメントと融合した単一IFN−ベータ |
| CN101965200B (zh) * | 2008-02-27 | 2013-06-19 | 诺沃-诺迪斯克有限公司 | 缀合的因子ⅷ分子 |
| AU2009262476C1 (en) * | 2008-06-24 | 2016-06-02 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
-
2011
- 2011-02-10 EP EP15159991.7A patent/EP2977055A1/en not_active Withdrawn
- 2011-02-10 EP EP11703448A patent/EP2536754A1/en not_active Withdrawn
- 2011-02-10 WO PCT/EP2011/051959 patent/WO2011101284A1/en not_active Ceased
- 2011-02-10 CN CN201510524808.4A patent/CN105153313A/zh not_active Withdrawn
- 2011-02-10 JP JP2012553267A patent/JP2013519699A/ja not_active Withdrawn
- 2011-02-10 CN CN201180009864.4A patent/CN102770450B/zh not_active Expired - Fee Related
- 2011-02-10 US US13/574,686 patent/US9493543B2/en not_active Expired - Fee Related
-
2016
- 2016-02-08 JP JP2016021624A patent/JP6185097B2/ja not_active Expired - Fee Related
- 2016-10-04 US US15/285,138 patent/US20170015729A1/en not_active Abandoned
-
2017
- 2017-07-26 JP JP2017144266A patent/JP2017190342A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013519699A5 (enExample) | ||
| JP6559642B2 (ja) | Fviiiの特定部位の変更 | |
| JP6527918B2 (ja) | 第viii因子組成物、ならびに組成物の作製方法および用途 | |
| TWI686404B (zh) | 重組因子viii蛋白 | |
| JP2018104459A (ja) | 血友病の治療に適する化合物 | |
| JP2017503509A5 (enExample) | ||
| JP2019531087A (ja) | 高グリコシル化ヒト血液凝固第viii因子の融合タンパク質、その調製方法、および使用 | |
| JP2015527882A5 (enExample) | ||
| JP6605593B2 (ja) | 第viii因子およびフォン・ヴィルブランド因子ペプチドを含む製剤 | |
| JP2010202664A (ja) | 第viii因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト | |
| JP2016522219A (ja) | 血友病の治療に適する化合物 | |
| JP2015519313A (ja) | 血友病の治療に適する医薬組成物 | |
| JP2025121974A (ja) | Siglec依存的免疫応答をモジュレートするポリペプチド | |
| WO2020063562A1 (zh) | 突变型单链人凝血因子viii融合蛋白及其制备方法与用途 | |
| WO2017050820A1 (en) | Fviii fusion proteins | |
| KR20250168493A (ko) | 개선된 약동학을 갖는 fviii-vwf 융합 단백질 |